Skip to main content
SpringerLink
Log in

Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Background

Fatty liver is a common disease in developed countries. We investigated the frequency of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives.

Methods

In this study, we evaluated 105 patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD), 121 patients with hepatitis C (61 patients with fatty liver and 60 patients without fatty liver), 50 patients with inflammatory bowel disease (IBD), and 109 patients with dyspepsia as a control group.

Results

There was no difference for sex, mean age, and marital status among the groups, except that patients with IBD were younger than others (p < 0.001). The frequency of cancer in family was as follows: 18 % in IBD, 9 % in dyspepsia, 28 % in hepatitis C with hepatic steatosis, 21.5 % in hepatitis C without steatosis, and 27 % in NAFLD (p = 0.006). Then, we divided the study group into two groups—group 1: IBD + dyspepsia + hepatitis C without hepatic steatosis, and group 2: hepatitis C with hepatic steatosis + NAFLD—and performed the same analysis. We found that the frequency of cancer in family was 16 % in group 1 (the patients without fatty liver) vs. 24.4 % in group 2 (those with fatty liver; p = 0.037). We also investigated the rate of operation in patients. The results were as follows: 33 % in group 1 vs. 43 % in group 2 (p = 0.043).

Conclusions

Independently of the underlying chronic diseases, occurrence of fat in the liver increased the frequency of operation in patients with fatty liver and the rate of cancer in their first-degree relatives. Understanding the underlying causes of fatty liver forms might decrease the cancer frequency in the population and number of operation in patients with fatty liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

NAFLD:

Nonalcoholic fatty liver disease

IBD:

Inflammatory bowel disease

HCC:

Hepatocellular carcinoma

HF:

High-fat

HFCS:

High fructose corn syrup

References

  1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23. PMID:12668987. doi:10.1053/jhep.2003.50161.

    Article  PubMed  Google Scholar 

  2. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9. PMID:10051466. doi:10.1002/hep.510290347.

    Article  CAS  PubMed  Google Scholar 

  3. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis. 2004;8:639–71. PMID:15331068.

    Article  PubMed  Google Scholar 

  4. Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16(18):2223–6. PMID:20458758.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Basaranoglu M, Turhan N, Sonsuz A, Basaranoglu G. Mallory-Denk bodies in chronic hepatitis. World J Gastroenterol. 2011;17(17):2172–7. PMID:21633525. doi:10.3748/wjg.v17.i17.2172.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Canbakan B, Senturk H, Canbakan M, Toptas T, Tuncer M. Reliability of caspase activity as a biomarker of hepatic apoptosis in nonalcoholic fatty liver disease. Biomark Med. 2011;5:813–5. PMID:22103615.

    Article  CAS  PubMed  Google Scholar 

  7. Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D’Agostino RB, Gaziano JM, Vasan RS. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation. 2007;116:480–8.

    Article  PubMed  Google Scholar 

  8. Marchesini G, Ridolfi V, Nepoti V. Hepatotoxicity of fast food? Gut. 2008;57:568–70. PMID:18408097. doi:10.1136/gut.2007.143958.

    Article  PubMed  Google Scholar 

  9. Basaranoglu M, Sonsuz A, Senturk H, Akin P. The low incidence of primary liver disease in patients with nonalcoholic steatohepatitis. J Hepatol. 2001;35(5):684–5. PMID:11690720.

    Article  CAS  PubMed  Google Scholar 

  10. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:987–95. PMID:18772365. doi:10.1152/ajpgi.90272.2008.

  11. Neuschwander-Tetri BA, Ford DA, Acharya S, Gilkey G, Basaranoglu M, Tetri LH, Brunt EM. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids. 2012;47(10):941–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sonsuz A, Basaranoglu M, Bilir M, Senturk H, Akin P. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2002;97:495. PMID:11866302.

  13. Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol. 2011;17(36):4055–62. PMID:22039318.

  14. Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl. 2011. PMID:22213627. doi:10.1002/prca.201100052.

  15. Brunt EM. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis. 2012;30(Suppl. 1):61–8. PMID:23075870. doi:10.1159/000341127.

    Article  PubMed  Google Scholar 

  16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

    Article  PubMed  Google Scholar 

  17. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  18. Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep. 2010;10:93–100.

    Article  CAS  PubMed  Google Scholar 

  19. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011;7(7):1003–15. doi:10.7150/ijbs.7.1003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Basaranoglu M, Basaranoglu G, Bugianessi E. Carbohydrate and NAFLD. Fructose as a weapon of mass destruction. Hepatobiliary surgery nutrition. http://dx.doi.org/10.3978/j.issn.2304-3881.2014.11.05. http://www.thehbsn.org/article/view/5213.

  21. Basaranoglu M, Neuschwander-Tetri Brent A. Nonalcoholic fatty liver disease: clinical features and pathogenesis. Gastroenterol Hepatol. 2006;2:282–91.

    Google Scholar 

Download references

Conflict of interest

The authors declare that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Internal Medicine, Medical School, BezmiAlem Vakif University, 34000, Istanbul, Turkey

    Metin Basaranoglu MD, PhD, Billur Canbakan, Kemal Yildiz, Bahadir Ceylan, Birol Baysal, Omer Uysal & Hakan Senturk

Authors
  1. Metin Basaranoglu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Billur Canbakan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kemal Yildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bahadir Ceylan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Birol Baysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Omer Uysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hakan Senturk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Metin Basaranoglu MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Basaranoglu, M., Canbakan, B., Yildiz, K. et al. Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives. Wien Klin Wochenschr 128, 691–694 (2016). https://doi.org/10.1007/s00508-015-0744-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-015-0744-4

Keywords

Search

Navigation